scholarly journals The hypoglycemic effect of freeze‐dried fermented mulberry mixed with soybean on type 2 diabetes mellitus

2021 ◽  
Author(s):  
Xiao‐Shan Long ◽  
Sen‐Tai Liao ◽  
Er‐Na Li ◽  
Dao‐Rui Pang ◽  
Qian Li ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Hypoglycemic Effect ◽  
Freeze Dried

PHARMACOEPIDEMIOLOGICAL STUDY OF THE EFFECTIVENESS OF HYPERGLYCEMIA CORRECTION AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH LIVER LESIONS WITH DIABETES LOWERING THERAPY AND ESSENTIAL PHOSPHOLIPID DRUGS

2020 ◽  
pp. 28-40
Author(s):  
Valery B. Maksimenko ◽  
Luka A. Gromakov ◽  
Svetlana E. Sinyutina
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
Relative Risk ◽  
Fold Increase ◽  
Hypoglycemic Effect ◽  
Liver Lesions ◽  
Essential Phospholipids

The aim of the study is to study the possibility of improving the effectiveness of hyperglycemia treatment among patients with type 2 diabetes mellitus by correcting the structural-functional state of the liver using essential phospholipid preparations. Materials and methods. The cohort retrospective study examined the medical histories of 1050 patients with type 2 diabetes mellitus, among whom 205 had liver complications. Diagnosis of steatohepatitis among patients with type 2 diabetes mellitus was verified based on increased activity of hepatic transaminases and serum bilirubin concentration. Metabolic syndrome was verified according to 3 criteria: abdominal obesity, dyslipidemia and arterial hypertension. Fatty hepatosis was diagnosed based on an ultrasound study. Three times during the course of treatment of the patients the glycemic profile was studied. Patients were divided into study groups: type 2 diabetes mellitus without liver diseases (control); type 2 diabetes mellitus with liver disease (chronic persistent hepatitis, chronic steatohepatitis) received standard diabetes reduction therapy; type 2 diabetes mellitus with the same liver pathology, which was additionally prescribed essential phospholipid drugs (essentiale forte intravenously 10 ml/day and per os at 500 mg; essliver - per os 500 mg (1 cap) 3 times/day). Statistical methods : calculating the value of the average, the error of the average, the reliability of the differences according to the Student criterion, the percentage of differences between groups. Pharmacoepidemiological methods evaluated the hazard ratio and the odds ratio of the therapeutic effect of essential phospholipids. Results . Patients with liver lesions make up 19.5 % among patients with type 2 diabetes mellitus. Among them, patients with fatty hepatosis account for 3.3 %; with steatohepatitis - 3 %; with metabolic syndrome in combination with fatty hepatosis and steatohepatitis - 14.3 %. More than a 4-fold increase in relative chance and a 2-fold increase in relative risk of hypoglycemic effect in type 2 diabetes mellitus and hepatic steatosis is likely due to the fat-lysis and membranotropic effects of essential phospholipids on the liver. 1.7-fold increase in relative chance and 1.5-fold increase in relative risk of hypoglycemic effect in type 2 diabetes mellitus and steatohepatitis appears to be due to choleretic effect of essential phospholipids.

scholarly journals HYPOGLYCEMIC EFFECT OF KAIDARYADI KWATHA YOGA IN TYPE 2 DIABETES MELLITUS

2020 ◽  
pp. 47-49
Author(s):  
Archana V S ◽  
N. Subhash Babu ◽  
Aswathy. S
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Hypoglycemic Effect ◽  
Control Group ◽  
P Value ◽  
Before And After ◽  
Insulin Dependent ◽  
Behavioural Factors

Type 2 diabetes mellitus, previously referred to as ‘Non insulin dependent’ or ‘maturity onset diabetes’ is a heterogenous condition characterised by variable defects in both insulin secretion and insulin action. In conjunction with genetic susceptibility, type 2 diabetes mellitus is brought on by environmental and behavioural factors such as sedentary lifestyle and obesity. Due the resultant microvascular and macrovascular complications, it possess great economic and functional burden. This study was undertaken to clinically evaluate the hypoglycemic effect of the well known Ayurvedic formulation Kaidaryadi kwatha yoga in Type 2 Diabetes mellitus. The study was conducted pre and post without control group in 30 patients. FBS, PPBS and HbA1c was done before and after treatment. Statistical analysis revealed significant reduction in FBS, PPBS and HbA1c levels with a p value <0.001. Thus the formulation was found to be effective in reducing the glycemic levels and symptoms of Type 2 Diabetes mellitus.

scholarly journals Hypoglycemic Effect of Laminaria japonica Polysaccharide in a Type 2 Diabetes Mellitus Mouse Model

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Xiaodan Li ◽  
Zhuqin Yu ◽  
Shaohua Long ◽  
Yunliang Guo ◽  
Delin Duan
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Serum Insulin ◽  
Fasting Blood Glucose ◽  
Laminaria Japonica ◽  
Hypoglycemic Effect ◽  
Mice Model

The aim is to investigate the hypoglycemic effect of Laminaria japonica polysaccharides (LJPS) on type 2 diabetes mellitus (T2DM) mice model. 60 healthy male mice have been used in the experiment. T2DM animal mode was prepared by high fatty forage feeding and intraperitoneal injection with alloxan. Diabetic mice were orally supplied with LJPS. Then their blood was collected for various biomedical measurements of fasting blood glucose (FBG), serum insulin, and amylin. Treatment with LJPS significantly reduced fasting blood glucose (P<0.05) and increased the levels of insulin and amylin in serum (P<0.05). Overall, the study presented that LJPS can reverse several components of T2DM. Therefore, LJPS may become a new oral candidate medicine for the treatment of diabetes.

HYPOGLYCEMIC EFFECT OF INDOBUFEN,AN ANTIAGGREGATING AGENT,IN ELDERLY DIABETIC PATIENTS

1987 ◽  
Author(s):  
F Barzizza ◽  
G Belloni ◽  
E Trespi ◽  
A Venturini ◽  
I Richichi
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Elderly Patients ◽  
Hypoglycemic Effect ◽  
Hypoglycemic Agents ◽  
Diabetic Patients ◽  
Atherosclerotic Vascular Disease

Inibition of platelet aggregation is of value in therapy for Transient Ischemic Attacks(TIA).We observed 2 consecutive elderly patients with type 2 diabetes mellitus(DM)and TIA,in whom chronic treatment with Indobufen(I) provoked a reduction of blood glucose levels; for this reason we started a cross-over study to assess the possible hypoglycemic effect of I in elderly patients with DM.Ten patients(5 males,mean age 75±5 years)with DM and TIA have been included in our study. After 1 month of diet treatment(1)all patients took either placebo tablets 2)or I 200mg every 12 hours for 4 weeks in a random cross-over fashion.After each period a daily blood glucose profile has been obteined. Results are the following:Indobufen in the dose of 200 mg every 12 hours has an hypoglycemic effect. This side effect can be dangerous in patients already treated with hypoglycemic agents, but can be usefull as a single drug therapy for aged patients with type 2 diabetes mellitus and atherosclerotic vascular disease.

scholarly journals Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day

2021 ◽  
Vol 93 (10) ◽  
pp. 1203-1208
Author(s):  
Igor A. Sklyanik ◽  
Marina V. Shestakova
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Carbohydrate Metabolism ◽  
Fasting Blood Glucose ◽  
The Body ◽  
Hypoglycemic Effect ◽  
Antihyperglycemic Therapy

Background. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are innovative drugs that effectively reduce glycemic levels and overweight in patients with type 2 diabetes mellitus (T2DM). However, the criteria for predicting the hypoglycemic effect of this group of drugs have not been practically defined. Aim. To assess the factors contributing to the achievement the glycemia normalization in patients with diabetes mellitus and obesity by adding to antihyperglycemic therapy (AT) a drug from the GLP-1 RA group liraglutide 3.0 mg per day. Materials and methods. A single-center, prospective, non-randomized study was provided. The objects of the study were patients with T2DM and obesity (n=22). Liraglutide 3.0 mg per day was added to the current AT of patients. Initially, the parameters of carbohydrate metabolism, hormones of the incretin system on an empty stomach and during the mixed-meal test, insulin resistance using the euglycemic hyperinsulinemic clamp test, and body composition were studied. After 9 months of therapy, all studies were repeated and a search for possible predictors of the carbohydrate metabolism normalization was made. Results. The body mass index of patients decreased from 42.4 [37.7; 45.0] to 35.9 [33.0; 40.9] kg/m2. Fasting blood glucose and glycated hemoglobin levels decreased from 9.02 [7.40; 11.37] mmol/L and 7.85 [7.43; 8.65]% up to 5.90 [5.12; 6.18] mmol/L and 6.40 [5.90; 6.60]%, respectively. 14 (63.6%) patients reached normoglycemia. Insulin resistance according to the clamp test did not change over the study. Basal concentrations of oxyntomodulin, glycentin and the area under the GLP-1, oxyntomodulin, glycentin curve significantly decreased 9 months after liraglutide administration. The prognostic marker of the achievement of normoglycemia during therapy with liraglutide 3.0 mg/day is the level of endogenous GLP-15.5 pmol/L before the appointment of arGPP-1 therapy. Conclusion. The concentration of endogenous GLP-1 before the appointment of liraglutide therapy at a dose of 3.0 mg per day can be used for prediction the drug hypoglycemic effect and achieving normoglycemia possibility.

Sign in / Sign up

Export Citation Format

Share Document